Differences among the elderly in the treatment costs of colorectal cancer: How important is race?

Medical Care

Volumn 45, Issue 5, 2007, Pages 420-430

  Wright, George E ^a   Barlow, William E ^b   Green, Pamela ^a   Baldwin, Laura Mae ^a   Taplin, Stephen H ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer cost of care; Disparities; Economics; Medicare; Race and ethnicity

Indexed keywords

AFRICAN AMERICAN; AGED; ARTICLE; CANCER REGISTRY; CANCER STAGING; CAUCASIAN; COHORT ANALYSIS; COLORECTAL TUMOR; COMPARATIVE STUDY; COST OF ILLNESS; ECONOMICS; ETHNOLOGY; FEMALE; HEALTH CARE COST; HUMAN; MALE; MEDICAL FEE; MEDICARE; STATISTICS; UNITED STATES;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; COHORT STUDIES; COLORECTAL NEOPLASMS; COST OF ILLNESS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEE-FOR-SERVICE PLANS; FEMALE; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; MALE; MEDICARE; NEOPLASM STAGING; SEER PROGRAM; UNITED STATES;

EID: 34247338130     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlr.0000257184.93944.80     Document Type: Article

References (39)

1. Brown ML, Riley GF, Schussler N, et al. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002;40:IV-104-IV-117.
2. U.S. Cancer Statistics Working Group. United States cancer statistics: 2002 incidence and mortality. 2005. Available at: http://www.cdc.gov/cancer/ npcr/uscs. Accessed January 4, 2007.
3. Engstrom PF, Benson AB 3rd, Cohen A, et al. NCCN colorectal cancer practice guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park). 1996;10:140-175.
4. National Institutes of Health. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444-1450.
5. Brown ML, Nayfield SG, Shibley LM. Adjuvant therapy for stage III colon cancer: economics returns to research and cost-effectiveness of treatment. J Natl Cancer Inst. 1994;86:424-430.
6. Schrag D, Gelfand SE, Bach PB, et al. Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results - Medicare. J Clin Oncol. 2001;19:3712-3718.
7. Schrag D, Cramer LD, Bach PB, et al. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001;93:850-857.
8. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004;101:3-27.
9. Ball JK, Elixhauser A. Treatment differences between blacks and whites with colorectal cancer. Med Care. 1996;34:970-984.
10. Freeman HP, Alshafie TA. Colorectal carcinoma in poor blacks. Cancer. 2002;94:2327-2332.
11. Cooper GS, Yuan Z, Landefeld CS, et al. Surgery for colorectal cancer: race-related differences in rates and survival among Medicare beneficiaries. Am J Public Health. 1996;86:582-586.
12. Singh GK, Miller BA, Hankey BF, et al. Area Socioeconomic Variations In U.S. Cancer Incidence, Mortality, Stage, Treatment, and Survival, 1975-1999. NCI Cancer Surveillance Monograph Series, Number 4. NIH Publication No. 035417. Bethesda, MD: National Cancer Institute; 2003.
13. Kelz RR, Gimotty PA, Polsky D, et al. Morbidity and mortality of colorectal carcinoma surgery differs by insurance status. Cancer. 2004; 101:2187-2194.
14. Baldwin LM, Dobie SA, Billingsley K, et al. Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst. 2005;97:1211-1220.
15. Potosky AL, Riley GF, Lubitz JD, et al. Potential for cancer related health services research using a linked Medicare-tumor registry data-base. Med Care. 1993;31:732-748.
16. Brown ML, Riley GF, Potosky AL, et al. Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med Care. 1999;37:1249-1259.
17. Riley GF, Potosky AL, Lubitz ID, et al. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care. 1995;33:828-841.
18. Taplin SH, Barlow W, Urban N, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst. 1995;87:417-426.
19. Fireman BH, Quesenberry CP, Somkin CP, et al. Cost of care for cancer in a health maintenance organization. Health Care Financ Rev., 1997;18:51-76.
20. Barlow WE, Taplin SH, Yoshida CK, et al. Cost comparison of mastectomy versus breast-conserving therapy for early-stage breast cancer. J Natl Cancer Inst. 2001;93:447-455.
21. Warren J. Overview of the SEER-Medicare data. Paper Delivered at the SEER Medicare Data Users Workshop. Bethesda, MD: National Cancer Institute; 1998.
22. Bach PB, Guadagnoli E, Schrag D, et al. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care. 2002;40:IV-19-IV-25.
23. Medicare Prospective Payment Commission. Annual Report to Congress. Washington, DC: 2003.
24. Lamers LM. Health-based risk adjustment: is mpatient and outpatient diagnostic information sufficient? Inquiry. 2001;38:423-431.
25. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health. 1992;82:703-710.
26. Fiscella K, Franks P. Impact of patient socioeconomic status on physician profiles: a comparison of census-derived and individual measures. Med Care. 2001;39:8-14.
27. Geronimus AT, Bound J. Use of census-based aggregate variables to proxy for socioeconomic group: evidence from national samples. Am J Epidemiol. 1998;148:475-486.
28. Morrill R, Cromartie J, Hart LG. Metropolitan, urban, and rural commuting areas: toward a better depiction of the US settlement system. Urban Geography. 1999;20:727-748.
29. WWAMI Rural Health Research Center. Rural-urban commuting area codes (RUCAs). Available at: http://depts.washington.edu/uwrhrc/. Accessed January 4, 2007.
30. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40:IV-55-IV-61.
31. Virnig BA, Warren JL, Cooper GS, et al. Studying radiation therapy using SEER-Medicare-linked data. Med Care. 2002;40:IV-49-IV-54.
32. Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ. 1999;18:153-171.
33. Escarce J.T, Kapur K. Racial and ethnic differences in public and private medical care expenditures among aged Medicare beneficiaries. Milbank Q. 2003;81:249-275, 172.
34. Oehlert GW. A note on the delta method. Am Stat. 1992;46:27-29.
35. The Dartmouth Atlas of Health Care in the United States, 1999. Chicago, IL: American Hospital Association; 1999.
36. Schrag D. The price tag on progress - chemotherapy for colorectal cancer. N Engl J Med. 2004;351:317-319.
37. Barbeau EM, Krieger N, Soobader MJ. Working class matters: socio-economic disadvantage, race/ethnicity, gender, and smoking in NHIS 2000. Am J Public Health. 2004;94:269-278.
38. Nilunger L, Diderichsen F, Burstrom B, et al. Using risk analysis in Health Impact Assessment: the impact of different relative risks for men and women in different socio-economic groups. Health Policy. 2004;67:215-224.
39. Thorpe KE, Howard D. Health insurance and spending among cancer patients. Health Aff (Milhvood). 2003;Suppl Web Exclusives:W3-189-198.